



Clinical trial results:

A Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance

Summary

EudraCT number	2017-003206-41
Trial protocol	GB
Global end of trial date	29 August 2018

Results information

Result version number	v1 (current)
This version publication date	30 September 2020
First version publication date	30 September 2020

Trial information

Trial identification

Sponsor protocol code	TAK-954-2002
-----------------------	--------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03477903
WHO universal trial number (UTN)	U1111-1208-1831
Other trial identifiers	18/NE/0139: NRES

Notes:

Sponsors

Sponsor organisation name	Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd.
Sponsor organisation address	35 Landsdowne St., Cambridge, United States, 02139
Public contact	Study Manager, Takeda Development Centre Europe Ltd., + 44 1256 894003,
Scientific contact	Study Manager, Takeda Development Centre Europe Ltd., + 44 1256 894003,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 August 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 August 2018
Global end of trial reached?	Yes
Global end of trial date	29 August 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study is to assess the treatment effect of intravenous TAK-954 in improving the average daily protein adequacy received through enteral nutrition in critically-ill participants developing EFI.

Due to the constraints/requirements of the EudraCT database and concern for participant data privacy, zero subjects are being listed in the below fields.

Protection of trial subjects:

The informed consent form, subject authorization form and subject information sheet (if applicable) describe the planned and permitted uses, transfers, and disclosures of the subject's personal health information for purposes of conducting the study. The informed consent form and the subject information sheet (if applicable) further explain the nature of the study, its objectives, and potential risks and benefits, as well as the date informed consent is given.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 August 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 99999
Worldwide total number of subjects	99999
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	99999
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

99999 is "Not applicable" value or 0 participants. Due to the constraints/requirements of the EudraCT database and concern for participant data privacy, zero subjects are being listed in the below fields.

Pre-assignment

Screening details:

N/A

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer, Assessor

Arms

Arm title	Overall
Arm description: -	
Arm type	Experimental
Investigational medicinal product name	TAK-954
Investigational medicinal product code	TAK-954
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

0.1 milligram (mg), intravenously, administered as 60 minute-infusion, once daily along with 2 milliliter (mL) normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.

Number of subjects in period 1	Overall
Started	99999
Completed	99999

Baseline characteristics

Reporting groups

Reporting group title	Overall
-----------------------	---------

Reporting group description: -

Reporting group values	Overall	Total	
Number of subjects	99999	99999	
Age Categorical			
Due to the low number of participants enrolled at only 1 site, 0 participants are reported due to the risk of identification of a person.			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	99999	99999	
From 65-84 years	0	0	
85 years and over	0	0	
Age Continuous			
Due to the low number of participants enrolled at only 1 site, 0 participants are reported due to the risk of identification of a person.			
Units: years			
arithmetic mean	0		
standard deviation	± 0	-	
Gender Categorical			
Due to the low number of participants enrolled at only 1 site, 0 participants are reported due to the risk of identification of a person.			
Units: Subjects			
Female	99999	99999	
Male	0	0	

End points

End points reporting groups

Reporting group title	Overall
Reporting group description: -	

Primary: Average Daily Protein Adequacy Over the First 5 Days of Treatment

End point title	Average Daily Protein Adequacy Over the First 5 Days of Treatment ^[1]
-----------------	--

End point description:

Average daily protein adequacy received through enteral nutrition is defined as the percentage of goal protein delivered per day, where percentage of goal protein delivered is calculated as the ratio of actual protein achievement to the total participant-specific target protein prescribed. The value for each of the 5 days was averaged. No data displayed because Endpoint has zero total participants analyzed.

End point type	Primary
----------------	---------

End point timeframe:

Days 1 to 5

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Not applicable

End point values	Overall			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[2]			
Units: number				

Notes:

[2] - Due to low number of participants enrolled at only 1 site, 0 reported due to risk of identification.

Statistical analyses

No statistical analyses for this end point

Secondary: Average Daily Protein Adequacy Over the Study Treatment Period

End point title	Average Daily Protein Adequacy Over the Study Treatment Period
-----------------	--

End point description:

Average daily protein adequacy received through enteral nutrition is defined as percentage of goal protein delivered per day, where percentage of protein goal delivered is calculated as the ratio of actual protein achievement to the total participant-specific target protein prescribed. The value for each of the 14 days was averaged. No data displayed because Endpoint has zero total participants analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 1 to 14

End point values	Overall			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[3]			
Units: number				

Notes:

[3] - Due to low number of participants enrolled at only 1 site, 0 reported due to risk of identification.

Statistical analyses

No statistical analyses for this end point

Secondary: Average Daily Change in 24-hour Gastric Residual Volume (GRV) Over the First 5 Days of Study Treatment

End point title	Average Daily Change in 24-hour Gastric Residual Volume (GRV) Over the First 5 Days of Study Treatment
-----------------	--

End point description:

GRV is defined as the volume of fluid remaining in the stomach at a point in time during enteral nutrition feeding. The value for each of the 5 days was averaged. No data displayed because Endpoint has zero total participants analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 1 to 5

End point values	Overall			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[4]			
Units: number				

Notes:

[4] - Due to low number of participants enrolled at only 1 site, 0 reported due to risk of identification.

Statistical analyses

No statistical analyses for this end point

Secondary: Average Daily Caloric Adequacy

End point title	Average Daily Caloric Adequacy
-----------------	--------------------------------

End point description:

Average daily caloric adequacy received through enteral nutrition was defined by percentage of goal calories achieved per day (percentage calorie goal achieved=actual calorie achievement/total participant-specific target calories). The values in the 5-day period and the 14-day period were averaged. No data displayed because Endpoint has zero total participants analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 1 to 5 and Days 1 to 14

End point values	Overall			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[5]			
Units: number				

Notes:

[5] - Due to low number of participants enrolled at only 1 site, 0 reported due to risk of identification.

Statistical analyses

No statistical analyses for this end point

Secondary: Time to Resolution of Enteral Feeding Intolerance (EFI)

End point title	Time to Resolution of Enteral Feeding Intolerance (EFI)
-----------------	---

End point description:

Time to resolution of EFI is defined as the time needed to achieve GRV less than or equal to 250 ml in the absence of vomiting/retching. No data displayed because Endpoint has zero total participants analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 1 to 14 or until resolution of EFI, whichever occurs first

End point values	Overall			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[6]			
Units: number				

Notes:

[6] - Due to low number of participants enrolled at only 1 site, 0 reported due to risk of identification.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Achieving at Least 80% of Daily Goal Calories

End point title	Percentage of Participants Achieving at Least 80% of Daily Goal Calories
-----------------	--

End point description:

No data displayed because Outcome Measure has zero total participants analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Days 1 to 14 or end of treatment

End point values	Overall			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[7]			
Units: number				

Notes:

[7] - Due to low number of participants enrolled at only 1 site, 0 reported due to risk of identification.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants Achieving at Least 80% of Daily Goal Protein

End point title	Percentage of Participants Achieving at Least 80% of Daily Goal Protein
End point description: No data displayed because Outcome Measure has zero total participants analyzed.	
End point type	Secondary
End point timeframe: Days 1 to 14 or end of treatment	

End point values	Overall			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[8]			
Units: number				

Notes:

[8] - Due to low number of participants enrolled at only 1 site, 0 reported due to risk of identification.

Statistical analyses

No statistical analyses for this end point

Secondary: Ctrough: Observed Concentration at the End of a Dosing Interval of TAK-954

End point title	Ctrough: Observed Concentration at the End of a Dosing Interval of TAK-954
End point description:	
End point type	Secondary
End point timeframe: Day 5 pre-dose	

End point values	Overall			
Subject group type	Reporting group			
Number of subjects analysed	0 ^[9]			
Units: number				

Notes:

[9] - Due to low number of participants enrolled at only 1 site, 0 reported due to risk of identification.

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

Up to 4 days

Adverse event reporting additional description:

At each visit the investigator had to document any occurrence of AEs and abnormal laboratory findings. Any event spontaneously reported by the subject or observed by the investigator was recorded, irrespective of the relation to study treatment. Due to the low number of participants enrolled at only 1 site, 0 reported due to risk of identification.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	0
--------------------	---

Reporting groups

Reporting group title	TAK-954 0,1 mg
-----------------------	----------------

Reporting group description:

TTAK-954 0.1 milligrams (mg), intravenously, administered as 60 minute-infusion, once daily along with 2 milliliters (mL) normal saline injection, intravenously, three times a day for a minimum of 5 days up to a maximum of 14 days.

Serious adverse events	TAK-954 0,1 mg		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 99999 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	TAK-954 0,1 mg		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 99999 (0.00%)		

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Not applicable

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported